Sinovac Biotech is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Co.'s products include: Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a vaccine against influenza; Panflu, a vaccine against the H5N1 influenza virus; Split Viron Pandemic Influenza Vaccine, an influenza vaccine; Panflu.1, a vaccine against the influenza A H1N1 virus; Mumps Vaccine; Inlive, a treatment for HFMD; and Varicella Vaccine, a vaccine for disease caused by the varicella-zoster virus. We show 11 historical shares outstanding datapoints in our coverage of SVA's shares outstanding history.
Understanding the changing numbers of SVA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SVA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SVA by allowing them to research SVA shares outstanding history
as well as any other stock in our coverage universe. |
Free SVA Email Alerts:
Video: Shares Outstanding Importance
